.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01E_ProteinKinaseInhibitors.L01EH03_Tucatinib.Tucatinib .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01E_ProteinKinaseInhibitors.L01EH03_Tucatinib.Tucatinib| name: | Tucatinib |
| ATC code: | L01EH03 | route: | oral |
| n-compartments | 2 |
Tucatinib is an oral, selective HER2 tyrosine kinase inhibitor approved for the treatment of HER2-positive metastatic breast cancer, typically in combination with other agents. It is currently approved by drug agencies such as the FDA and EMA.
Pharmacokinetic parameters reported in adult patients with advanced (metastatic) HER2-positive breast cancer, generally female adults.
Zhang, D, et al., & Topletz-Erickson, A (2024). Population Pharmacokinetic Analysis of Tucatinib in Healthy Participants and Patients with Breast Cancer or Colorectal Cancer. Clinical pharmacokinetics 63(10) 1477–1487. DOI:10.1007/s40262-024-01412-0 PUBMED:https://pubmed.ncbi.nlm.nih.gov/39368039